I'd like to know your protocol in the study of disease evolution progressive fibrosing interstitial diseaseat (UIP, NSIP mainly) with High-Resolution -Computed -Tomography (HRCT). My question arises mainly from incomplete compilation of final guidelines by the major scientific Thoracic Society (ATS, ERS, JRS, ALAT). It is not clear whether the examination technique is to date the volumetric HRCT versus incremental HRCT study (my technique now is prone volumetric HRCT when I have a clinical suspect of interstitial disease), there is uncertain definition on the position that should be prone to me in patients with interstitial fibrosing disease. What dose radiation must be used in proper study of patients with disease of this type? Is certainly necessary to take into account that the first factor to consider is the age of the subject studied. When expiration scans? And also on the timing for follow-up in the proper management of the patient with interstitial fibrosing disease not is clear when the Radiologist is legitimated to perform their routine testing (8 months? 12 months?).

The HRCT follow-up of the patient must always be subordinate to an alteration or progressive worsening of functional and clinical data or must be independent of it and management for patients fibrotic must be the same?